MDF Releases RFA for DM1 Genome Editing Research

Published on Tue, 08/14/2018

Request for Applications - Development of a Genome Editing Strategy for Myotonic Dystrophy Type 1

MDF is pleased to announce a Request for Applications (RFA) for the Development of a Genome Editing Strategy for Myotonic Dystrophy Type 1. MDF intends to issue two 2-year awards of up to $250,000 total cost each for projects that address the evaluation of genome editing strategies for DM1 that target the DMPK gene.

The focus of this RFA is early stage discovery and development of in vivo genome editing technologies in academic laboratories or other nonprofit research institutions, utilizing state-of-the-art knowledge. The goal is to establish a proof of concept for a therapeutic that is not incremental, but has a substantial level of effect across the multiple body systems impacted by the DM1 disease.

Collaborations between experts in genome editing technologies and those with strong track records in myotonic dystrophy research are strongly encouraged.

Application Details

Applications are due November 30, 2018. Applicants are encouraged to contact Chief Executive Officer, Molly White, with any questions about this RFA or the scientific content of their proposals. Technical issues should be directed to MDF Grants Manager Elizabeth Habeeb-Louks.

Click here to read the full Request for Applicationsaccess the RFA Cover SheetRead summary report from the 2018 MDF Gene Editing Workshop.